ERLEADA

• tagApproval60 co-mentions · 15 sources
• drugapalutamide60 co-mentions · 15 sources
• companyJanssen Biotech Inc30 co-mentions · 15 sources
• tagSmall Molecule30 co-mentions · 15 sources

Trials studying ERLEADA

• phase3An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLASactive not recruitingn=1,503
• phase1A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Canceractive not recruitingn=19
• phase3A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomyactive not recruitingn=2,517
• phase2Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.recruitingn=192
• phase3An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)active not recruitingn=982
• phase3A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Canceractive not recruitingn=1,207
• —A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamideactive not recruitingn=504
• phase3PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.recruitingn=120